BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment.
Guidelines have been compiled by The Joint Tuberculosis Committee of the British Thoracic Society to quantify the risks of reactivation of tuberculosis with anti-tumour necrosis factor alpha (anti-TNF-alpha) treatment. These guidelines are intended to inform respiratory physicians, gastroenterologists, rheumatologists and dermatologists, together with specialist nurses in those disciplines.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000465:Algorithms; D000995:Antitubercular Agents / Q000009:adverse effects; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008875:Middle Aged; D009169:Mycobacterium tuberculosis; D012307:Risk Factors; D014376:Tuberculosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D000995:Antitubercular Agents; D014409:Tumor Necrosis Factor-alpha